Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 9:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 62 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypoglycemic Agents Clear all
Completed No phase listed Observational Results available

A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents

NCT01077323
View directory record Official record
Conditions
Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)
Interventions
exenatide, Other antidiabetic therapies, No diabetes therapy
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
363,766 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 30, 2026, 9:11 AM EDT
Completed No phase listed Observational

Neurodevelopment of Hypoglycemic Neonates

NCT04875624
View directory record Official record
Conditions
Neonatal Hypoglycemia, Neurodevelopmental Disorders
Interventions
Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4)
Diagnostic Test
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Months to 24 Months
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 30, 2026, 9:11 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Effect of C-peptide on Hypoglycemic Counterregulation

NCT06470295
View directory record Official record
Conditions
Hypoglycemia, Type 1 Diabetes
Interventions
Saline, C-peptide
Other · Biological
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 40 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 4 Interventional

Lifestyle Modification for Obesity-Related Type 2 Diabetes

NCT00415688
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Overweight, Obesity
Interventions
Low carbohydrate, ketogenic diet, Low glycemic index, reduced calorie diet
Behavioral
Lead sponsor
Robert C. Atkins Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 25, 2006 · Synced Sep 30, 2026, 9:11 AM EDT
Terminated Phase 4 Interventional Results available

Oral Anti Diabetic Agents in the Hospital

NCT04416269
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM)
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 3 Interventional

Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)

NCT00653341
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
insulin glargine, NPH human insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
30 Years to 70 Years
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 20, 2009 · Synced Sep 30, 2026, 9:11 AM EDT
Completed No phase listed Observational Results available

Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy

NCT02140645
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
166,613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents

NCT03285594
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin, Insulin glargine (HOE901), Placebo, Oral Antidiabetes Drugs (OADs)
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Huntington Park, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Sep 30, 2026, 9:11 AM EDT
Withdrawn Early Phase 1 Interventional

Glucagon-like Peptide-1 in Type 1 Diabetes

NCT04355832
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Glucagon-like peptide-1, Placebos
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Liraglutide in Parkinson's Disease

NCT02953665
View directory record Official record
Conditions
Parkinson Disease
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
25 Years to 85 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin

NCT00036504
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin Lispro low mixture
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years to 79 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
13
States / cities
La Jolla, California • Walnut Creek, California • New Britain, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Sep 30, 2026, 9:11 AM EDT
Recruiting Phase 3 Interventional

A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes

NCT04786262
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
Interventions
VX-880, VX-017
Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
12
States / cities
Duarte, California • San Francisco, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 30, 2026, 9:11 AM EDT
Completed No phase listed Observational

Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting

NCT01326598
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
V-Go™
Device
Lead sponsor
Valeritas, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
25
States / cities
Chula Vista, California • San Francisco, California • Danbury, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent

NCT01511198
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
39
States / cities
Vestavia Hills, Alabama • Tucson, Arizona • Carlisle, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 2 Interventional Results available

A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator

NCT00631007
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
INT131 besylate, Pioglitazone HCl, Placebo
Drug
Lead sponsor
InteKrin Therapeutics, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
59
States / cities
Carmichael, California • Los Angeles, California • San Diego, California + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

NCT00528879
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
28
States / cities
Tempe, Arizona • Encino, California • Fresno, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Sep 30, 2026, 9:11 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Effects of Pulsatile Intravenous Insulin Delivery on Hypoglycemic Unawareness

NCT01029639
View directory record Official record
Conditions
Hypoglycemia
Interventions
Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
20 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Sep 30, 2026, 9:11 AM EDT
Not listed Phase 1 Interventional

UVA Islet Cell Transplantation in Patients With Type I Diabetes

NCT00605592
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Pancreatic Islets of Langerhans Cell Transplant
Procedure
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2009 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Not applicable Interventional Results available

Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm® X54 System

NCT01148862
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
The MiniMed Paradigm® X54 System
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
16 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Escondido, California • Stanford, California • Aurora, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 4 Interventional

Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment

NCT01076842
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Insulin-Levemir, Exenatide-Bayetta, Insulin-Levemir and Exenatide-Bayetta, SenseWear Pro3® armband, DexCom CGM
Drug · Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 2 Interventional

Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents

NCT00099333
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, Insulin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
5
States / cities
Chula Vista, California • Butte, Montana • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Sep 30, 2026, 9:11 AM EDT
Terminated Not applicable Interventional Results available

Perioperative Continuous Glucose Monitoring

NCT05937373
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Continuous Glucose monitor, Standard of Care
Device · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Sep 30, 2026, 9:11 AM EDT
Withdrawn Not applicable Interventional

Developing a Model to Predict Inpatient Hypoglycemic Episodes

NCT05989256
View directory record Official record
Conditions
Hypoglycemic Events, Hyperglycemic Therapy
Interventions
EndoTool, glucose management team, standard of care glucose management
Diagnostic Test · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Sep 30, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Results available

Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production

NCT03852901
View directory record Official record
Conditions
Empaglifozin, Physiological Effects of Drugs, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors
Interventions
empagliflozin (Jardiance) 25 mg
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 30, 2026, 9:11 AM EDT